Almirall - LBTSF STOCK NEWS

Dr. Jorge Gallardo Ballart will retire as Chairman of Almirall's Board of Directors and as a board member effective from the upcoming General Shareholders Meeting on May 6, 2022. Mr. Carlos Gallardo Piqué, currently Vice-President of the Board, has been appointed as the new Chairman. Carlos has extensive international healthcare experience, including a tenure at Pfizer and leadership roles at Almirall. He aims to enhance the company’s growth in Medical Dermatology. Dr. Gallardo recognized the company's promising future under the new leadership.

Dr. Jorge Gallardo Ballart will retire as Chairman and Board member of Almirall effective after the General Shareholders Meeting on May 6, 2022. Mr. Carlos Gallardo Piqué, currently Vice-President, will succeed him. Carlos brings extensive healthcare experience, having served in significant roles at Almirall and as a venture capitalist in digital health. Carlos expressed excitement about leading Almirall towards becoming a Medical Dermatology leader and improving patient care. The Board thanked Jorge for his 50-year leadership, highlighting his contributions to the company.

Almirall reported strong results for 2021, with Core Net Sales of €809.8 million (+7%) and Core EBITDA of €211.3 million (+17%), achieving the high end of its guidance. The growth was driven by the performance of its EU dermatology portfolio, particularly Ilumetri and Seysara, and solid cash flow generation of €233.8 million. The company announced a proposed dividend of €0.19 per share and introduced 2022 guidance forecasting mid-single-digit growth in Core Net Sales. Almirall also reported progress in its R&D pipeline with positive results for lebrikizumab in atopic dermatitis.

Almirall has reported strong financial results for the first nine months of 2021, with Core Net Sales reaching €601.7 million, a 6.2% year-on-year increase, and Core EBITDA climbing by 20.3% to €164.2 million. The company has also tightened its 2021 guidance for Core EBITDA to between €200 million and €215 million. Notable growth drivers include the successful launches of Ilumetri and Klisyri, with the latter showing strong early adoption in Germany. However, normalized net income fell 17.2% year-on-year to €61.4 million, indicating some challenges in profitability.

Almirall U.S. supports The Skin Cancer Foundation's mobile screening program, Destination Healthy Skin, which offers free skin cancer checks across the U.S. This initiative aims to raise awareness of skin cancer, with the RV screening program projected to travel roughly 9,000 miles and visit 21 cities this year. Since its inception, the program has conducted over 25,000 screenings and identified 10,000 potential skin cancers, including 440 melanomas. Early detection significantly increases survival rates, making these screenings crucial for combating skin cancer.

Almirall, S.A. reported H1 2021 financial results, with Core Net Sales reaching €415.5 million, an 8% increase year-on-year, and Core EBITDA rising 40.4% to €125.6 million. However, the company reported a Net Loss of €42.8 million due to an impairment of €100 million related to Seysara®, the US Legacy Portfolio, and a missed option payment. Operating Cash Flow was €109.8 million. The company anticipates strong product launches in H2 2021 and has updated full-year guidance for Core EBITDA to between €195 million to €215 million.

Almirall S.A. announced the European Commission's approval of Klisyri® (tirbanibulin) for treating actinic keratosis (AK) on the face or scalp in adults. This first-in-class topical medication offers a convenient treatment regimen with one application daily for five days, demonstrating significant efficacy in clinical trials. Two pivotal phase III studies showed that 44% and 54% of patients achieved complete clearance of AK lesions, respectively. The drug is also under review for marketing authorization in Switzerland and Great Britain, continuing Almirall's commitment to innovation.

Almirall S.A. announced a positive opinion from the European Medicines Agency (EMA) for its product Klisyri (tirbanibulin), aimed at treating actinic keratosis (AK) on the face and scalp. Klisyri represents a first-in-class microtubule inhibitor, requiring only a 5-day treatment regimen. The clinical trials demonstrated significant efficacy, achieving 100% lesion clearance in 44% to 54% of patients. The European Commission is expected to follow the CHMP's recommendation, with an approval anticipated within 60 days, paving the way for a late 2021 launch in Europe.

Almirall, a biopharmaceutical company, reported Q1 2021 financial results, highlighting a 5% increase in Core Net Sales to €215.4 million, aided by one-time positive impacts totaling €16 million. Core EBITDA rose 46% year-on-year to €68 million. Notable products like Ilumetri® saw a 90% sales increase to €17 million, and Seysara® rebounded with 20% growth. The company maintains guidance for mid-single-digit growth in Core Net Sales and EBITDA between €190-210 million. CEO Gianfranco Nazzi expressed confidence in future growth driven by new product launches.